國家衛生研究院 NHRI:Item 3990099045/4334
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12189/12972 (94%)
造訪人次 : 956102      線上人數 : 793
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/4334


    題名: Development of EGFR-targeting nanomedicine for effectively and noninvasively treats lung cancer patients by aerosol delivery
    其他題名: World Congress on Medical Physics and Biomedical Engineering: Micro- and Nanosystems in Medicine, Active Implants, Biosensors
    作者: Tseng, CL;Wu, YH;Yu, SW;Yang, KC;Lin, FH
    貢獻者: Division of Medical Engineering Research
    摘要: Lung cancer is a harmful form of cancer. The long-term survival rate of lung cancer patients treated by conventional modalities remains far from satisfactory. Encapsulated anticancer drugs in nanocarriers, can protect not only the integrity of drugs during transport but also the normal tissues from the toxicity. To develop an effective drug delivery system for lung cancer therapy, gelatin nanoparticles (GPs) were modified with NeutrAvidin <sup>FITC</sup>-biotinylated epidermal growth factor (bEGF) to form EGF receptor (EGFR)-seeking nanoparticles (GP-Av-bEGF). Cisplatin, a key drug used in the chemotherapy with sever side effect, was incorporated in the nanocarriers for active targeting to reduce toxicity. Furthermore, these nanocarriers were given to mice via inhalation of aerosol droplets which were generated by a nebulizer and delivered to mice model of lung cancer via aerosol. To summarize, the in vivo targeting ability of GP-Av-bEGF was examined by fluorescence images obtained from live mice showed that these nanoparticles could target the cancerous lungs in a more specific manner by aerosol delivery. And gelatin nanoparticles loaded with cisplatin and decorated with EGF tumor-specific ligand (GP-PtbEGF) were also successfully developed. Their in vitro and in vivo targeting ability and anticancer effect were confirmed. This treatment showed that GP-Pt-bEGF had stronger antitumor activity and was less toxic compared with other cisplatin formulas. Furthermore, these formulations were given to mice with lung cancer via aerosol delivery and showed that inhaled GP-Pt-bEGF could target EGFR-overexpressing cells to achieve high cisplatin dosage in cancerous lungs. The aerosol delivery of nanocarriers was demonstrated here. Simple aerosol delivery of targeted drug carriers may prove useful for the clinical treatment of lung cancer patients to eliminate patient complaints associated with the frequent intravenous injection.
    日期: 2009-09
    關聯: IFMBE Proceedings. 2009 Sep;25(8):347-350.
    Link to: http://dx.doi.org/10.1007/978-3-642-03887-7
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000291667000100
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77949903150
    顯示於類別:[林峯輝] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    SCP77949903150.pdf745KbAdobe PDF547檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋